Every material Form 8-K LeonaBio, Inc. has filed with the SEC since August 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LeonaBio disclosed that its Series A Common Warrants, issued in December 2025 in a private placement, became exercisable on September 18, 2026 and remain exercisable until October 19, 2026. If all warrants are exercised for cash, the company would receive approximately $146.2 million, but the filing warns that some may expire unexercised or be exercised on a cashless basis if the resale registration statement is not effective, which would bring in less or no cash.
Warrants cover 23,031,494 common shares at an exercise price of $6.35 per share.
Warrants became exercisable September 18, 2026 and expire to exercise after October 19, 2026.
Full cash exercise would provide approximately $146.2 million of additional capital.
LeonaBio said it has enrolled the 500th subject in its Phase 3 ELAINE-3 trial of lasofoxifene with abemaciclib in ESR1-mutated metastatic breast cancer. The filing also sets the start of the exercise window for 23,031,494 Series A Common Warrants at $6.35 per share, which could bring about $146.2 million in cash if fully exercised, and states that the enrollment announcement triggers that window.
500th subject enrolled in the ELAINE-3 Trial (NCT05696626), announced August 26, 2026
23,031,494 Series A Common Warrants with an exercise price of $6.35 per share, issued in connection with the December 2025 Private Placement
Warrants become exercisable after the latest of June 30, 2026, this announcement, and FDA action on Eli Lilly's imlunestrant with abemaciclib, and no later than October 31, 2026
Full exercise would provide approximately $146.2 million; warrants expire no later than November 30, 2026
LeonaBio reported a second-quarter 2026 net loss of $19.0 million, or $0.80 per share, up from $7.0 million, or $1.78 per share, a year earlier. The company said higher spending on the Phase 3 ELAINE-3 trial for lasofoxifene drove the increase, and cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, which shareholders may want to track against the company's funding needs.
Net loss was $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared with $7.0 million, or $1.78 per share, a year earlier.
R&D expenses rose to $12.9 million from $3.7 million, driven mainly by clinical trial spend for the ELAINE-3 trial.
Cash, cash equivalents and investments were $51.1 million at June 30, 2026, down from $88.3 million at December 31, 2025; net cash used in operations was $37.9 million for the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LeonaBio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →